Final Results of the RHAPSODY trial: A multi ‐center, Phase 2 trial using a continual reassessment method to determine the safety and tolerability of 3K3A‐APC, a Recombinant Variant of Human Activated Protein C, in combination with tissue plasminogen activator, mechanical thrombectomy or both in moderate to severe acute ischemic stroke

This article is protected by copyright. All rights reserved.

Source: Annals of Neurology - November 18, 2018 Category: Neurology Authors: Patrick Lyden, Kent E. Pryor, Christopher S. Coffey, Merit Cudkowicz, Robin Conwit, Ashutosh Jadhav, Robert N. Sawyer, Jan Claassen, Opeolu Adeoye, Shlee Song, Peter Hannon, Natalia S. Rost, Archana Hinduja, Michel Torbey, Jin ‐Moo Lee, C Tags: Research Article Source Type: research